•
Jun 30, 2022

Abbott Q2 2022 Earnings Report

Achieved strong growth and raised full-year EPS guidance.

Key Takeaways

Abbott announced strong second-quarter results, with worldwide sales increasing by 10.1 percent on a reported basis and 14.3 percent on an organic basis. The company is raising its full-year EPS guidance.

Total worldwide sales increased 10.1 percent on a reported basis and 14.3 percent on an organic basis.

Global COVID-19 testing-related sales were $2.3 billion in the quarter.

FreeStyle Libre sales were approximately $1.1 billion, representing sales growth of 18.7 percent on a reported basis and 25.6 percent on an organic basis.

Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to at least $3.50 and adjusted diluted earnings per share to at least $4.90.

Total Revenue
$11.3B
Previous year: $10.2B
+10.1%
EPS
$1.43
Previous year: $1.17
+22.2%
Organic Sales Growth
14.3%
Previous year: 35%
-59.1%
Gross Profit
$6.32B
Previous year: $5.28B
+19.9%
Cash and Equivalents
$8.94B
Previous year: $8.66B
+3.2%
Free Cash Flow
$2.03B
Previous year: $1.72B
+18.4%
Total Assets
$74.2B
Previous year: $73.3B
+1.3%

Abbott

Abbott

Forward Guidance

Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to at least $3.50. Excluding specified items, Abbott is raising its projected adjusted diluted earnings per share to at least $4.90 for the full-year 2022.